Search
Dexfenfluramine
go.drugbank.com/drugs/DB01191ApprovedIllicitWithdrawnFor a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss.
Varenicline
go.drugbank.com/drugs/DB01273ApprovedInvestigationalPfizer is conducting an additional safety study of the drug, results of which are expected in late 2015.
Homatropine methylbromide
go.drugbank.com/drugs/DB00725ApprovedIt can be used together with antacids or other medicine in the treatment of peptic ulcer. It may also be used to prevent nausea, vomiting, and motion sickness.
Relugolix
go.drugbank.com/drugs/DB11853ApprovedInvestigational[A225926] In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management … [L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022.[L42150] Relugolix has also been studied in the symptomatic treatment of endometriosis.
Tividenofusp alfa
go.drugbank.com/drugs/DB17628ApprovedInvestigationalWhile standard ERTs can treat systemic symptoms, they are unable to cross the blood-brain barrier (BBB) to address the progressive cognitive decline and neurological impairment seen in the majority of … Developed by Denali Therapeutics, tividenofusp alfa received FDA approval on March 25, 2026, under the accelerated approval pathway [L56097, L56099].
Elacestrant
go.drugbank.com/drugs/DB06374ApprovedInvestigationalElacestrant is a non-steroidal small molecule and an estrogen receptor (ER) antagonist. … [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.
Oxybutynin
go.drugbank.com/drugs/DB01062ApprovedInvestigational[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.[A185990] … [A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and
Endometrial Carcinoma
go.drugbank.com/conditions/DBCOND0031833Synonyms: Ca endometrium, Endometrial CaTezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L4894] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion … [L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018.